Abstract
What is known and objective: Voriconazole has significant drug interactions due to metabolism by CYP enzymes. Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone are not well described. Case description: An 84-year-old male was started on voriconazole for a fungal brain abscess. He was readmitted due to clinical failure thought to be the result of subtherapeutic voriconazole concentrations. Dexamethasone was identified as a potential cause due to its induction of CYP enzymes. This interaction was substantiated by sequential troughs that demonstrated a rise in voriconazole concentrations as dexamethasone was tapered off. What is new and conclusion: Therapeutic drug monitoring for patients on voriconazole and dexamethasone is essential to prevent suboptimal clinical outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | 441-443 |
Number of pages | 3 |
Journal | Journal of Clinical Pharmacy and Therapeutics |
Volume | 41 |
Issue number | 4 |
DOIs | |
State | Published - Aug 1 2016 |
Keywords
- dexamethasone
- drug–drug interaction
- fungal brain abscess
- therapeutic drug monitoring
- voriconazole
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)